Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page updated how it displays the last update timestamp: replaced 'Last Update Posted' with 'Last Update Posted (Estimated)'.
    Difference
    0.0%
    Check dated 2025-10-13T06:59:48.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Core content and versioning updated: added a government-operating-status notice and new version/date metadata; removed older dates and revision v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T04:28:40.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Upgrade version from v3.0.2 to v3.1.0 with an added update marker; no substantive content or critical data changes detected.
    Difference
    0.3%
    Check dated 2025-09-29T01:19:24.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Updated to Revision: v3.0.2, replacing v3.0.1. Also removed the 'Back to Top' element—a minor UI change with limited impact on core content.
    Difference
    0.1%
    Check dated 2025-09-14T18:46:45.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-07T13:10:09.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as detailed information on various medical compounds and diseases, particularly related to diffuse large B-cell lymphoma and immunotherapy agents like pembrolizumab.
    Difference
    4%
    Check dated 2025-08-31T06:21:45.000Z thumbnail image

Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.